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ABSTRACT
Context: Preterm births occur in 11% of all births worldwide, but account for more than 85% of perinatal morbidity and mortality. 
One of the best predictors to assess the risk of preterm labor (PTL) is by measuring fetal fibronectin (fFN) in cervicovaginal 
secretions (CVS). In addition, measurement of cervicovaginal fluid fFN is a good negative predictor of spontaneous PTL in 
both symptomatic and asymptomatic high‑risk women after 22 weeks of pregnancy.
Aim: We aimed to evaluate the diagnostic accuracy of qualitative cervicovaginal beta‑human chorionic gonadotropin (β‑hCG) 
versus qualitative fFN for prediction of PTL in asymptomatic high‑risk women during antenatal care.
Settings and Design: This prospective observational study was undertaken at Egypt, Zagazig University Hospitals. In all, 
220 with singleton pregnancies and having risk factors for spontaneous preterm birth were included in this study.
Materials and Methods: Cervicovaginal fluid sampling was undertaken at 24 weeks gestational age for qualitative β‑hCG 
and qualitative fFN assessment. Women were categorized into two arms: women who delivered preterm and women who 
delivered at term.
Statistical Analysis Used: Data were presented as mean, ±standard deviation, number, and percentage. Chi‑square test (χ2) 
was used for comparison between groups with regard to qualitative variables; validity of the test is done using sensitivity, 
specificity, positive predictive value (PPV), and negative predictive value (NPV).
Results: As regarding qualitative β‑hCG assessment for prediction of PTL, sensitivity, specificity, PPV, and NPV were 72%, 
85%, 41%, and 95.5%, respectively. As regarding qualitative fFN assessment for prediction of PTL in the same studied 
group, sensitivity, specificity, PPV, and NPV were 73%, 87%, 38%, and 96%, respectively.
Conclusion: Our study showed that qualitative β‑hCG assessment in cervicovaginal fluid can be used as an alternative method 
to qualitative fFN assessment as it is a valid test, more available, and not expensive in prediction of PTL in asymptomatic 
high‑risk patients.
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Introduction
Preterm labor (PTL) refers to the onset of labor after fetal 
viability but before completing 37 weeks of pregnancy. 
The diagnostic criteria of threatened PTL are onset of 
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frequent uterine contractions (at least four contractions per 
20 minutes) and cervical changes in the form of effacement 
and dilatation, that is, 80% cervical effacement and at 
least 2 cm dilatation (or cervical length <1 cm). Preterm 
births occur in 11% of all births worldwide, but account for 
more than 85% of perinatal morbidity and mortality.[1] Fetal 
mortality and morbidities such as neurological problems, 
retinopathy of prematurity, hyaline membrane disease, and 
necrotizing enterocolitis are common sequels of preterm 
delivery.[2-4]
Fetal amnion is the main source of fibronectin which is a 
glycoprotein found in high concentration in the liquor amnii 
and fetal membrane. One of the best predictors to assess 
the risk of PTL is by measuring the fetal fibronectin (fFN) 
in the cervicovaginal secretions (CVS).[5] Mechanical or 
inflammatory-mediated disruption of the uteroplacental 
interface before birth leads to the release of fFN in CVS.[6] It 
is absent during 24–37 weeks of pregnancy. Its presence in 
the CVF is a sign of PTL within 7 days.[7]
Measurement of cervicovaginal fluid fFN is a good negative 
predictor of spontaneous PTL in both symptomatic[8] and 
asymptomatic high-risk women after 22 weeks of pregnancy.[9] 
They found that in symptomatic patients between 24 and 
34 weeks of pregnancy, measurement of fFN provides a high 
negative predictive value (NPV) for continuing pregnancy 
beyond 7 days after testing and for prolonging gestation 
beyond 34 weeks.[10,11]
In addition to fFN, beta-human chorionic gonadotropin (β-hCG) 
was also studied for its relation with PTD. Various studies 
showed an increased concentration of the marker during 
spontaneous preterm birth. Monitoring of β-hCG level in CVF 
as a marker for PTD can be a useful predictor in symptomatic 
women.[12] Gurbuz et al. showed that increased concentration 
of β-hCG in CVF was found in women with PTD, and in 
contrast to fFN, this test has the benefits of low cost and 
wide availability.[13]
Guvenal et al. reported that cervicovaginal β-hCG >28 mIU/mL 
had the ability to predict preterm delivery between 24 and 
36 weeks gestation with a sensitivity, specificity, positive 
predictive value (PPV), and NPV of 87, 65, 28, and 97%, 
respectively, in women with threatened PTL. The kits 
used for “pregnancy test” in urine can detect β-hCG levels 
of >25 mIU/mL, and so those kits could detect the β-hCG level 
which predicts preterm delivery according to a previously 
mentioned study.[14]
The aim of our study is to evaluate the diagnostic accuracy of 
qualitative assessment of cervicovaginal fFN versus qualitative 
assessment of cervicovaginal β-hCG for prediction of PTL in 
asymptomatic high-risk women during antenatal care.
Materials and Methods
This prospective observational study was performed from 
May 2015 to September 2017 at Zagazig University Hospitals. 
This study was approved by the Research Ethical Committee 
of Zagazig University Hospitals. Written informed consent 
was obtained from all participants. In all, 220 women with 
singleton pregnancies and risk factors for spontaneous 
preterm birth were included in this study. Cervicovaginal 
fluid sampling was undertaken for qualitative assessment of 
β-hCG and fFN at 24 weeks of gestation.
Inclusion criteria
There were past history of one or more spontaneous PTL 
or preterm premature rupture of membranes, previous 
spontaneous second-trimester miscarriage, previous cervical 
surgery, or an accidental finding of a cervical length of 25 mm 
or less in the current pregnancy.
Exclusion criteria
Prior sexual intercourse (within 24 h), or suspected or 
confirmed rupture of membranes, or who had visible 
vaginal bleeding on the swab were excluded. Early obstetric 
ultrasound (11–14 weeks of gestation) was performed to 
confirm the gestational age. Baseline demographic data, 
obstetric history, and risk factors were tabulated and 
analyzed. For qualitative assay of both β-hCG and fFN, vaginal 
specimens were collected by the following method.
Specimen collection
The anterior cervical lip was grasped with sponge forceps 
after introducing sterile Cusco speculum into the vagina. 
Before doing any cervical manipulations or introducing any 
vaginal material, sampling was performed. The Hologic 
specimen collection kit was used to collect specimens 
for this assay. The polyester tipped swab provided in the 
specimen collection kit should be inserted into the vagina and 
lightly rotated across the posterior fornix for approximately 
10 s to absorb cervicovaginal secretions. After obtaining the 
specimen, the swab was carefully removed from the vagina 
and was placed into a tube of buffer provided with specimen 
collection kit. Two specimen collection devices per patient 
were obtained, one for each assay. Specimen transport 
tubes were labeled with the patient’s name and any other 
identifying information required.
Qualitative assessment of β-hCG
It was performed as a bedside test. The swab was then 
inserted in a tube containing 0.75 mL of sterile normal saline 
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for dilution.[4] From this sample, three drops were used for 
a bedside β-hCG test using ACON–HCG one-step pregnancy 
test strip (Rapid Diagnostic Pvt. Ltd, India), with a detection 
cut-off value of 25 mIU/mL.
Qualitative assessment of fFN
It was done using quick check fFN test; it is a 10-min, one-step, 
visual test. The test strip was removed from the foil pouch and 
its lower end (indicated by the arrows) was inserted into the 
tube containing the extraction buffer for 10 min. A positive 
sample containing fFN will result in two lines in test strip 
and a negative sample will result in one control line in test 
strip.[11,12,15] All women were then followed up till delivery. 
Women were categorized into two arms: women who delivered 
preterm (before 37 completed weeks of gestation) and women 
who delivered at term (at or after 37 completed weeks of 
gestation). Cases with iatrogenic PTL were excluded from the 
study and were calculated among women who did not complete 
follow-up. We included only women with spontaneous PTL.
Sample size calculation
The sample size was calculated using Open Epi according 
to the following PPV of β-hCG assay mentioned in Abbott 
et al. (2015) which was 24% and that of fFN assay mentioned 
in Ibrahim et al. (2013) which was 79%. Therefore, at power 
of study 80% and confidence interval (CI) 95%, the sample 
size was calculated to be 220 cases.
Statistical analysis
The collected data were statistically analyzed using Statistical 
Package for Social Sciences (SPSS), version 20. Data were 
presented as mean, ± standard deviation, number, and 
percentage. Chi-square test (χ2) was used for comparison 
between groups with regard to qualitative variables; validity 
of the test is done using sensitivity, specificity, PPV, and NPV.
Results
Twenty cases were lost during follow-up, and therefore 
200 cases were included in the final analysis. Table 1 shows 
demographic data of the studied group. There is a highly 
significant (P < 0.00001) difference between women with 
preterm and term delivery as regards qualitative assessment 
of cervicovaginal β-hCG as shown in Table 2. In addition, 
there is a highly significant (P < 0.00001) difference between 
women with preterm and term delivery as regards qualitative 
assessment of cervicovaginal fFN as shown in Table 3. Table 4 
shows validity of qualitative assessment of cervicovaginal 
β-hCG (sensitivity 73.68%, specificity 87.85%, PPV 38.89%, NPV 
96.95%, accuracy 86.5%) and fFN (sensitivity 72%, specificity 
85.71%, PPV 41.86%, NPV 95.54%, accuracy 84%) in predicting 
PTL in asymptomatic high-risk women.
Discussion
PTL is a major cause of neonatal morbidity and mortality 
all over the world. There are various biomarkers that can 
identify patients with high risk of PTL. Therefore, those 
patients could be followed up and an effective management 
can be performed.[16,17]
Early diagnosis of asymptomatic women with high risk of 
PTL could help prevent it and gives the chance to enhance 
fetal lung maturity. If pregnant women are diagnosed as low 
risk for PTL, this could reduce the length of hospital stay and 
antenatal visits.
As regarding β-hCG assessment for prediction of PTL in the 
studied group, sensitivity, specificity, PPV, NPV, and accuracy 
were 73.68%, 87.85%, 38.89%, 96.95%, 86.5%, respectively.
Bernstein et al. evaluated β-hCG assessment in patients who 
had a risk of preterm delivery using a cut-off value >50 mIU/mL. 
The predictive values were sensitivity 50%, specificity 87%, 
PPV 33%, and NPV 93%.[16] A cut-off value 28 mIU/mL was used 
by Guvenal et al. between 24 and 36 weeks of pregnancy 
and reported sensitivity 87%, specificity 65%, PPV 28%, and 
NPV 97% for predicting preterm delivery.[14] A cut-off value 
of 77.8 mIU/mL was used by Garshasbi et al. and showed a 
sensitivity of 87%, specificity 97%, PPV 88.5%, and NPV 98% for 
predicting preterm delivery.[17] β-hCG value of >14 mIU/mL 
was the optimal cut-off value for predicting PTL <34 weeks 
with sensitivity 83.3%, specificity 85.5%, PPV 33.3%, and NPV 
98.3%.[18] The lower cut-off value of β-hCG assessment in this 
study as compared to a study by Bernstein et al. (>50 mIU/mL) 
and Garshasbi et al. (>77.8 mIU/mL) may be explained by the 
difference in the inclusion criteria of the study populations, 
earlier period of gestation, and a relatively low rate of 
PTL <34 weeks (8%) in this study.[16,18] Adhikari et al. showed 






No. of deliveries (median) 2 (1‑2)
GA at delivery (weeks)
M±SD 36.8±2.9
Risk factors
Previous preterm labor (37%)
Previous 2nd trimester miscarriage (16‑24 weeks) (20%)
Previous PROM (38%)
Previous cervical surgery 10 (5%)
SD, Standard deviation; BMI, Body mass index; GA, Gestational age; PROM, Premature 
rupture of membrane
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that hCG value of >14 mIU/mL was the ideal cut-off value for 
predicting PTL <34 weeks with sensitivity 83.3%, specificity 
85.5%, PPV 33.3%, and NPV 98.3%. Qualitative assessment of 
cervicovaginal fluid β-hCG at 26–36 weeks of gestation was 
valuable in the prediction of PTL in asymptomatic high-risk 
women. Using a cut-off value of 25 mIU/mL, the sensitivity was 
68.3%, specificity 96.1%, PPV 76.9%, NPV 94.3%, and diagnostic 
accuracy 91.8% to predict PTL.[19]
Regarding fFN assay for prediction of PTL in the same studied 
group, sensitivity, specificity, PPV, NPV, and accuracy were 72%, 
85.71%, 41.86%, 95.54%, and 84%, respectively.[20] Goldenberg 
et al. demonstrated that screening asymptomatic women for 
the presence of cervicovaginal fFN at 24 weeks of pregnancy had 
a high sensitivity in predicting more than 60% of spontaneous 
PTL within the following 4 weeks (sensitivity, 0.63; 95% 
CI: 0.4, 0.8; relative risk = 59.2, 95% CI: 35.9, 97.8) compared 
to women with a negative fFN assessment (<50 ng/mL).[21] 
Roman et al. reported high NPV and specificity for vaginal 
fFN in the prediction of PTL in asymptomatic high-risk 
women within 2 weeks of assessment.[22] The association 
between the presence of fFN and PTL in asymptomatic 
women was evaluated in a meta-analysis by Honest et al. The 
likelihood ratio was 4.0 (95% CI: 2.9, 5.5) for positive result of 
predicting PTL before 34 weeks of pregnancy.[7] Spontaneous 
preterm birth (<34 weeks) increased from 2.7%, 11.0%, 
14.9%, 33.9%, and 47.6% with increasing concentration of 
fFN (less than 10, 10–49, 50–199, 200–499, and 500 ng/mL 
or greater, respectively). A threshold of 50–199 ng/mL had 
sensitivity 46.5%, specificity 88.7%, PPV 23.7%, and NPV 
95.6%.[23] Leitich and Kaider found that serial sampling and 
assessment of fFN in asymptomatic high-risk women for PTL 
increased the sensitivity for delivery at less than 34 weeks 
of pregnancy to 92%, compared with 23% with a single fFN 
measurement. This meta-analysis confirmed that highest 
prediction using fFN testing is observed among high-risk 
patients and it also showed that serial fFN testing is the best 
to a single fFN test.[24]
Conclusion
β-hCG assessment in cervicovaginal secretion can be used as 
an alternative to fFN assessment as it is simple, available, and 
not expensive, and the validity of qualitative cervicovaginal 
β-hCG in high-risk patients for predicting PTL is nearly similar 
to that of cervicovaginal fFN assessment. The utility of β-hCG 
in our hospital is easily applicable, with early diagnosis and 
early interference which minimizes the rate of PTL in our 
locality.
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